Coverage / VERA / Trade Card

VERA

Vera Therapeutics, Inc

OPPORTUNISTIC BUY 2026-10-04 Data 8 days old USD 30.42 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 30.42
Buy <=wait / entry
USD 20.67
Trim >=take some off
USD 34.00
Thesis breakA failed or materially equivocal ORIGIN 3 final efficacy readout, an FDA refuse-...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case26%100 / 10026.0
Base case49%62 / 10030.4
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • FDA alignment on earlier ORIGIN Phase 3 analysis to support potential full approval for atacicept in IgAN
  • Planned sBLA submission to FDA in Q4 2026 for full approval of TRUTAKNA (atacicept)
  • ORIGIN 3 final efficacy analysis featured as late-breaking oral presentation at ASN Kidney Week 2026
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.